Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Buys 1,036 Shares

Key Points

• Pulse Biosciences COO Liane Rae Teplitsky purchased 1,036 shares at an average price of $48.23, totaling nearly $50,000. She also bought an additional 1,034 shares two days later for about $49,994.
• PLSE shares fell 2.0% to $47.57, despite trading near its 52-week high of $50.90. The company recently reported a larger-than-expected quarterly loss of $0.36 per share and revenue below analyst estimates.
• Analyst sentiment remains broadly positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $45.25; institutional investors own approximately 76.95% of the stock.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) COO Liane Rae Teplitsky acquired 1,036 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were bought at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the acquisition, the chief operating officer owned 1,036 shares in the company, valued at approximately $49,966.28. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Liane Rae Teplitsky also recently made the following trade(s):

• On Friday, August 28th, Liane Rae Teplitsky acquired 1,034 shares of Pulse Biosciences stock. The shares were purchased at an average cost of $48.35 per share, with a total value of $49,993.90.

Pulse Biosciences Trading Down 2.0%

PLSE stock traded down $0.99 during mid-day trading on Friday, reaching $47.57. 262,703 shares of the stock traded hands, compared to its average volume of 406,808. Pulse Biosciences, Inc has a 52-week low of $12.56 and a 52-week high of $50.90. The stock's fifty day moving average is $35.38 and its 200-day moving average is $27.00. The company has a market cap of $3.29 billion, a P/E ratio of -40.31 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The firm had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Equities research analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PLSE. Canaccord Genuity Group raised their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Oppenheimer reiterated an "outperform" rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pulse Biosciences in a report on Friday, July 17th. Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They issued a "buy" rating and a $58.00 price target for the company. Finally, Mizuho set a $45.00 price target on shares of Pulse Biosciences in a report on Monday, August 10th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pulse Biosciences has an average rating of "Moderate Buy" and an average price target of $45.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its stake in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock worth $26,000 after purchasing an additional 680 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Pulse Biosciences in the 2nd quarter valued at approximately $28,000. Tower Research Capital LLC TRC increased its holdings in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock worth $44,000 after buying an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock worth $70,000 after buying an additional 619 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in Pulse Biosciences during the second quarter valued at approximately $158,000. Hedge funds and other institutional investors own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source